Akero Therapeutics, Inc.

NASDAQ•AKRO

CEO: Dr. Andrew Cheng M.D., Ph.D.

セクター: Healthcare

業種: Biotechnology

上場日: 2019-06-20

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

連絡先情報

601 Gateway Boulevard, Suite 350, South San Francisco, CA, 94080, United States

650-487-6488

akerotx.com

時価総額

$4.50B

PER (TTM)

-15.3

19.7

配当利回り

52週高値

$58.40

52週安値

$21.34

52週レンジ

90%

順位52Top 73.5%

2.9

F-Score

改良版 Piotroski 分析

8年ファンダメンタル

弱い • 2.9 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2018-2025

財務ダッシュボード

Q3 2025 データ

売上高

$0.00+0.00%

直近4四半期の推移

EPS

-$0.99-5.71%

直近4四半期の推移

フリーCF

-$67.17M-4.62%

直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Strong Cash Position Maintained Total cash and marketable securities stood at $988.3M as of September 30, 2025, providing runway for ongoing operations.

Phase 3 Clinical Program Advances Global Phase 3 SYNCHRONY program enrollment continues for MASH treatment, building upon positive prior Phase 2b efficacy data.

R&D Investment Increased 22% Research and development expenses grew 22% to $217.7M for nine months, reflecting significant EFX advancement costs.

Definitive Merger Agreement Signed Definitive Merger Agreement signed with Novo in October 2025, offering stockholders $54.00 cash plus contingent value right.

リスク要因

Merger Transaction Uncertainty Transaction with Novo may not close, risking material adverse effects and potential $165.0M termination fee payment.

Clinical Trial Enrollment Difficulties Clinical trial enrollment and retention for SYNCHRONY program faces difficulty due to MASH diagnosis complexity and competition.

Continued Operating Losses Accumulated deficit reached $(1.049) B as of September 30, 2025; additional funding required if merger fails to support operations.

Manufacturing Supply Chain Reliance Heavy reliance on third-party manufacturers for complex EFX API and DP production introduces supply chain and quality risks.

見通し

SYNCHRONY Results Expected Expecting results from SYNCHRONY Real-World trial in first half of 2026 to support future marketing approval applications.

Stock Delisting Post-Merger Merger expected to close around year end; common stock will subsequently no longer be publicly listed on exchanges.

Anticipated R&D Expense Increase Anticipate substantial increase in research and development expenses supporting planned manufacturing and late-stage clinical activities.

Exploring Combination Therapies Exploring combination use of EFX with other therapies, like GLP-1 drugs, for potential greater effect in specific patient subpopulations.

同業比較

売上高 (TTM)

ARWR

$1.09B

+4081.8%

ACAD

$1.07B

+11.9%

ZLAB

$460.16M

+15.3%

粗利益率 (最新四半期)

KYMR

2763.6%

-2680.7pp

CRNX

111.8%

+0.0pp

ARWR

100.0%

+50.6pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
ARWR	$9.12B	45.1	36.1%	19.5%
KYMR	$6.89B	-23.3	-29.1%	4.7%
PRAX	$6.87B	-24.1	-58.7%	0.0%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

N/M

売上高の変動が大きい

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年5月11日

EPS:-

売上高:-

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし